Robert Lentz, MD

Assistant Professor, Medicine-Medical Oncology


FacultyPhoto
Medical School
  • MD, Vanderbilt University School of Medicine (2016)
Undergraduate School
  • BS, University of Michigan (MI) (2012)
Internship
  • McGaw Medical Center of Northwestern University Program (2017)
Residency
  • McGaw Medical Center of Northwestern University Program, Internal Medicine (2019)
Fellowships
  • University of Colorado, Hematology and Oncology (2022)
Languages
English
Department
Medicine-Medical Oncology

Research Interests

I am a member of the Phase One Expansion/Molecular Studies (POEMS, Phase I clinical trials) and Gastrointestinal (GI) Medical Oncology Programs. These comprehensive programs include multidisciplinary cancer clinics, tumor boards, and research endeavors (clinical trials). I am interested in developing new treatments for GI cancers which are more effective and safer, in order to improve the lives of my patients. My work is supported by multiple grants.

Publications

  • Amo-Aparicio J, Dominguez A, Atif SM, Dinarello A, Azam T, Alula KM, Piper M, Lieu CH, Lentz RW, Leal AD, Bagby SM, Messersmith WA, Karam SD, Dinarello CA, Pitts TM, Marchetti C. Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment. Cancer Res Commun. 2023 Sep 20;3(9):1899-1911. PubMed PMID: 37772994
  • Lentz RW, Friedrich TJ, Blatchford PJ, Jordan KR, Pitts TM, Robinson HR, Davis SL, Kim SS, Leal AD, Lee MR, Waring MRN, Martin AC, Dominguez ATA, Bagby SM, Hartman SJ, Eckhardt SG, Messersmith WA, Lieu CH. A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer. Clin Cancer Res. 2024 Sep 3;30(17):3768-3778. PubMed PMID: 38869830
  • Leary JB, Hu J, Leal A, Davis SL, Kim S, Lentz R, Friedrich T, Herter W, Messersmith WA, Lieu CH. Risk Without Reward: Differing Patterns of Chemotherapy Use Do Not Improve Outcomes in Stage II Early-Onset Colon Cancer. JCO Oncol Pract. 2024 Jul 24;:OP2400159. [Epub ahead of print] PubMed PMID: 39047212
  • Ueberroth BE, Lieu CH, Lentz RW. Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation. J Gastrointest Cancer. 2024 Sep;55(3):1448-1452. PubMed PMID: 38814411
  • Hawkins HJ, Yacob BW, Brown ME, Goldstein BR, Arcaroli JJ, Bagby SM, Hartman SJ, Macbeth M, Goodspeed A, Danhorn T, Lentz RW, Lieu CH, Leal AD, Messersmith WA, Dempsey PJ, Pitts TM. Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL). PLoS One. 2024;19(4):e0298808. PubMed PMID: 38598488
  • Robinson HR, Messersmith WA, Lentz RW. HER2-Positive Metastatic Colorectal Cancer. Curr Treat Options Oncol. 2024 May;25(5):585-604. PubMed PMID: 38539034

Professional Memberships

  • ASCO - American Association of Clinical Oncology, Member
  • AACR - American Association for Cancer Research, Member
  • SITC - Society for Immunotherapy of Cancer, Member
  • AGICC - Academic Gastrointestinal Cancer Consortium, Member

Practice Locations

UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

University of Colorado Cancer Center - Anschutz Medical Campus
1665 Aurora Ct
Aurora, CO 80045
720-848-0300

UCHealth Anschutz Outpatient Pavilion - Anschutz Medical Campus
1635 Aurora Ct
Aurora, CO 80045
720-848-0000

UCHealth Pancreas and Biliary Multidisciplinary Clinic - Anschutz Medical Campus
1665 Aurora Ct
3rd Floor
Aurora, CO 80045
1-855-824-7262

Hospital Affiliation
  • University of Colorado Hospital

Center Affiliations

Specialty Information

Specialties
  • Internal Medicine, Board Certification (2019)
  • Medical Oncology, Board Certification (2022)
Conditions & Treatments
  • Cancers - Anal Cancer
  • Cancers
  • Cancers - Biliary Cancer
  • Cancers - Colorectal Cancer
  • Cancers - Gastroenterologic Cancer (Colon, Stomach, Esophageal, Liver)
  • Cancers - Pancreatic Cancer
Clinical Interests
I am interested in Gastrointestinal Cancers (Colorectal, Pancreatic, Gastric, Esophageal, Hepatocellular, Gallbladder, Bile Duct, Anal, Abdominal Neuroendocrine, Abdominal Carcinoma of Unknown Primary), Drug Development (Experimental Therapeutics / Clinical Trials) and Translational Research.

Care Philosophy
I strive to provide patient-focused, personalized, multi-disciplinary care for patients with gastrointestinal (GI) cancers. Our team of specialized providers in Medical Oncology (chemotherapy, immunotherapy, and targeted therapies), Surgical Oncology, Radiation Oncology, Pathology, Molecular Pathology, Radiology, Interventional Radiology, Nuclear Medicine, Gastroenterology (both Hepatology and Interventional Endoscopy), Nutrition, and Integrative Medicine work together to achieve the best outcomes for our patients. We have weekly cancer-specific multidisciplinary clinics in pancreas, colorectal, gastroesophageal, liver, and neuroendocrine cancers where patients can meet all of their specialty providers in a single clinic visit.

Personal Interests
In my free time I enjoy hiking, skiing, and traveling with my wife and children.